Related Experiment Videos

New therapeutic strategies in the management of systemic sclerosis

Yannick Allanore1, Jèrôme Avouac, Julien Wipff

  • 1René Descartes University, Medical Faculty, Department of Rheumatology A, Cochin Hospital, Paris, France. yannick.allanore@cch.aphp.fr

Expert Opinion on Pharmacotherapy
|March 23, 2007
PubMed

Insights

Systemic sclerosis treatment is complex due to multi-organ involvement and involves vascular, immune, and fibroblast issues. Cardiovascular drugs may explain recent decreases in mortality, guiding current and future systemic sclerosis therapies.

Area of Science:

  • Rheumatology and Immunology
  • Dermatology
  • Cardiovascular Medicine

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease affecting skin and internal organs.
  • Pathogenesis involves vascular dysfunction, immune dysregulation, and fibroblast activation.
  • Current therapeutic strategies face challenges due to disease complexity and progression.

Purpose of the Study:

  • To review current therapeutic options for systemic sclerosis.
  • To explore potential future treatment strategies.
  • To discuss the impact of recent epidemiological findings on SSc management.

Main Methods:

  • Review of existing literature on systemic sclerosis pathogenesis and treatment.
  • Analysis of epidemiological data regarding mortality trends.
  • Synthesis of information on current and emerging therapies.

Main Results:

  • Systemic sclerosis pathogenesis is characterized by interconnected abnormalities in vascular, immune, and fibroblast systems.
  • A decrease in excess mortality has been observed, potentially linked to cardiovascular drug use.
  • Therapeutic approaches must address the multifaceted nature of SSc.

Conclusions:

  • Effective systemic sclerosis management requires addressing its diverse pathological pathways.
  • Cardiovascular medications may play a significant role in improving survival rates.
  • Future research should focus on integrated therapeutic strategies for systemic sclerosis.

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...